Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma

Vadim S. Koshkin(UCSF Helen Diller Family Comprehensive Cancer Center), Brian I. Rini(Vanderbilt University Medical Center), Timothy D. Gilligan(Cleveland Clinic), Petros Grivas(Seattle Cancer Care Alliance), Moshe Chaim Ornstein(Cleveland Clinic), Sumanta K. Pal(City of Hope), Michael B. Atkins(Georgetown University), Pedro C. Barata(University Hospitals Seidman Cancer Center), Nicholas J. Vogelzang(Comprehensive Cancer Centers of Nevada), William Kelly(Georgetown Lombardi Comprehensive Cancer Center), Tian Zhang(Duke Medical Center), Jorge A. García(Cleveland Clinic), Leonard J. Appleman(University of Pittsburgh), JoAnn Hsu(City of Hope), Daniel J. George(Duke University)
Journal for ImmunoTherapy of Cancer
January 29, 2018
10.1186/s40425-018-0319-9
Cited by 184

Related Papers

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|3.7k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
|New England Journal of Medicine|2013|3.3k